CD33 and neoplasm: designed Caspase9-CAR CD33T cells inducibly selected by ΔCD19, which could specifically lyse CD33+ MV4-11 tumor cells and primary leukemic blasts in vitro, following which CAR-T cells were largely eliminated by suicide gene activation (127).